Synergistic Action of AMX Associated with 1,8-Cineole and Its Effect on the ESBL Enzymatic Resistance Mechanism

Ahmed Amin Akhmouch, Soukayna Hriouech, Aouatef Mzabi, Mariam Tanghort, Hanane Chefchaou, Adnane Remmal * and Najat Chami

Department of Biology, Faculty of Science Dhar El Mahraz, University Sidi Mohammed Ben Abdellah, Atlas-Fez 1796, Morocco; ah.akhmouch@gmail.com (A.A.A.); hriouechsoukayna@gmail.com (S.H.); aouatef.mzabi@gmail.com (A.M.); mariamtanghort@gmail.com (M.T.); hanane.chefchaou@usmba.ac.ma (H.C.); chaminajat@gmail.com (N.C.)

* Correspondence: adnaneremmal@gmail.com; Tel.: +212-661532398

Abstract: The purpose of the present study is twofold. First, it aims to evaluate the synergistic action of the ß-lactam antibiotic; AMX is associated with 1,8-cineole on six clinical isolates of ESBL-producing Escherichia coli and Klebsiella pneumoniae strains. Second, it aims to determine the effect this association has on the ESBL enzymatic resistance mechanism. The synergistic action of AMX/1,8-cineole was evaluated using partial inhibitory concentrations (PIC), determined by a microplate, a checkerboard and time–kill assays. The effect of AMX/1,8-cineole associations on the ESBL enzymatic resistance mechanism was evaluated using a new optimized enzymatic assay. This assay was based on the determination of the AMX antibacterial activity when combined with 1,8-cineole (at subinhibitory concentrations) in the presence or absence of the ß-lactamase enzyme toward a sensitive E. coli strain. The results of both checkerboard and time–kill assays showed a strong synergistic action between AMX and 1,8-cineole. The results of the enzymatic assay showed that the combination of AMX with 1,8-cineole notably influences the enzymatic resistance of the reaction by decreasing the affinity of the ß-lactam antibiotic, AMX, to the ß-lactamase enzyme. All obtained results suggested that the AMX/1,8-cineole association could be employed in therapy to overcome bacterial resistance to AMX while reducing the prevalence of resistance.

Keywords: amoxicillin; 1,8-cineole; resistance; synergistic action; extended-spectrum beta-lactamases (ESBL); Escherichia coli; Klebsiella pneumoniae

1. Introduction

Antibiotic resistance has been a serious threat to public health in the past couple of decades, thus representing a challenge to medical research worldwide [1,2]. The production of ß-lactamase appears to be the most common resistance mechanism against ß-lactam antibiotics in Gram-negative bacteria and especially ESBL producers such as E. coli and K. pneumoniae, as confirmed by the World Health Organization [3]. To overcome resistance, many strategies have been considered. One of the most commonly adopted and successful strategies has been the co-administration of ß-lactam antibiotics with an enzyme inhibitor [4–7]. The inhibitors bind to ß-lactamase enzymes in an irreversible manner that deactivates the ß-lactamase, preventing it from destroying the accompanying ß-lactam antibiotic. The most commercially available inhibitor is clavulanate (CLA), which is used in combination with AMX. However, resistance to ß-lactamase inhibitors has also been reported [8]. As an alternative, several studies have reported the use of essential oils (EO) and their major compounds as synergistic agents to overcome ß-lactam antibiotics resistance [9–12]. In the present study, we have investigated the synergistic antibacterial effect of AMX when applied in combination with 1,8-cineole on multidrug-resistant bacteria. Then, the impact of this association on the ß-lactamase enzymatic reaction was examined.
2. Results
2.1. Determination of MIC and PIC Values

The MIC values of AMX and 1,8-cineole toward all of the six ESBL-producing strains were 50 mg/L and 100 mg/L, respectively. The obtained PIC values are shown in Tables 1 and 2. IC50 and IC25 of AMX toward the six tested strains were 1.1–1.7 mg/L and 0.5–0.9 mg/L, respectively. IC40, IC30 and IC20 of 1,8-cineole toward the six tested strains were 6.2–7.1 mg/L, 2.3–3.1 mg/L and 0.4–1.3 mg/L, respectively.

Table 1. PIC of AMX toward the six ESBL-producing strains.

| Strains  | IC50 (mg/L) | IC25 (mg/L) |
|----------|-------------|-------------|
| E. coli  |             |             |
| P956     | 1.1 ± 0.25  | 0.7 ± 0.14  |
| P933     | 1.3 ± 0.24  | 0.5 ± 0.10  |
| P7847    | 1.5 ± 0.13  | 0.8 ± 0.17  |
| K. pneumoniae |       |             |
| H1878    | 1.6 ± 0.17  | 0.9 ± 0.09  |
| H2001    | 1.3 ± 0.12  | 0.6 ± 0.14  |
| H1893    | 1.7 ± 0.09  | 0.8 ± 0.12  |

Table 2. PIC of 1,8-cineole toward the six ESBL-producing strains.

| Strains  | IC40 (mg/L) | IC30 (mg/L) | IC20 (mg/L) |
|----------|-------------|-------------|-------------|
| E. coli  |             |             |             |
| P956     | 6.2 ± 0.20  | 2.6 ± 0.12  | 1.2 ± 0.16  |
| P933     | 6.8 ± 0.14  | 2.3 ± 0.09  | 1.3 ± 0.24  |
| P7847    | 6.5 ± 0.10  | 2.7 ± 0.12  | 1.2 ± 0.11  |
| K. pneumoniae |       |             |             |
| H1878    | 7.1 ± 0.12  | 2.9 ± 0.12  | 0.4 ± 0.12  |
| H2001    | 6.9 ± 0.12  | 3.1 ± 0.10  | 0.7 ± 0.09  |
| H1893    | 6.8 ± 0.09  | 2.7 ± 0.09  | 0.6 ± 0.12  |

2.2. The Checkerboard Assay

Antibacterial activity of the different associations of AMX/1,8-cineole at PIC towards the six ESBL-producing strains is shown in Tables 3 and 4. The percentage of inhibition resulting when AMX at IC50 or IC25 was combined with 1,8-cineole at IC40, IC30 or IC20 was greater than the addition of the individual activities. Furthermore, the MIC of AMX and 1,8-cineole was significantly reduced in all bacteria. Total growth inhibition of all tested strains was observed when AMX at IC50 (1.1–1.7 mg/L) was associated with 1,8-cineole at IC40 (6.2–7.1 mg/L).

Table 3. Percentages of inhibition of AMX (IC 50%) associated with 1,8-cineole (IC 40%, IC 30% or IC 20%) toward the six ESBL-producing strains.

| Strains  | AMX/1,8-Cineole IC 50%/IC 40% | AMX/1,8-Cineole IC 50%/IC 30% | AMX/1,8-Cineole IC 50%/IC 20% |
|----------|-------------------------------|-------------------------------|-------------------------------|
| E. coli  |                               |                               |                               |
| P956     | 100.0 ± 0.0                   | 92.5 ± 0.56                   | 80.4 ± 0.69                   |
| P933     | 100.0 ± 0.0                   | 95.2 ± 0.75                   | 81.5 ± 0.59                   |
| P7847    | 100.0 ± 0.0                   | 90.8 ± 1.29                   | 79.4 ± 0.47                   |
| K. pneumoniae |                         |                               |                               |
| H1878    | 100.0 ± 0.0                   | 90.2 ± 0.68                   | 82.8 ± 0.94                   |
| H2001    | 100.0 ± 0.0                   | 93.7 ± 0.80                   | 81.2 ± 0.46                   |
| H1893    | 100.0 ± 0.0                   | 90.5 ± 0.25                   | 85.2 ± 0.41                   |
Table 4. Percentages of inhibition of AMX (IC 25%) associated with 1,8-cineole (IC 40%, IC 30% or IC 20%) toward the six ESBL-producing strains.

| Strains   | AMX/1,8-Cineole IC 25%/IC 40% | AMX/1,8-Cineole IC 25%/IC 30% | AMX/1,8-Cineole IC 25%/IC 20% |
|-----------|------------------------------|------------------------------|------------------------------|
| E. coli   |                              |                              |                              |
| P956      | 72.0 ± 0.38                  | 62.1 ± 0.22                  | 55.3 ± 0.75                  |
| P933      | 73.1 ± 0.45                  | 59.4 ± 0.32                  | 51.2 ± 0.48                  |
| P7847     | 70.1 ± 0.46                  | 63.3 ± 0.36                  | 53.4 ± 0.60                  |
| K. pneumoniae |                        |                              |                              |
| H1878     | 74.4 ± 0.28                  | 61.2 ± 0.26                  | 56.3 ± 0.38                  |
| H2001     | 72.4 ± 0.25                  | 60.2 ± 0.77                  | 53.9 ± 0.67                  |
| H1893     | 71.1 ± 0.29                  | 64.4 ± 0.34                  | 52.6 ± 0.35                  |

In terms of FIC index values of the different associations of AMX/1,8-cineole presented in Table 5, the combined application of AMX and 1,8-cineole produced a synergistic effect as defined by lower FIC indices. The FICI of AMX associated with 1,8-cineole was 0.08–0.10 against the six tested strains.

Table 5. FICI values for the different associations of AMX/1,8-cineole toward the six strains.

| Strains   | MIC Alone (mg/L) | MIC Combined (mg/L) | FIC-Index | Result   |
|-----------|------------------|---------------------|-----------|----------|
|           | AMX 1,8-Cineole  | AMX 1,8-Cineole     |           |          |
| E. coli   |                  |                     |           |          |
| P956      | 50 50            | 1.1 6.2             | 0.08      | Synergy  |
| P933      | 50 50            | 1.3 6.8             | 0.09      | Synergy  |
| P7847     | 50 50            | 1.5 6.5             | 0.10      | Synergy  |
| K. pneumoniae |            |                     |           |          |
| H1878     | 50 50            | 1.6 7.1             | 0.10      | Synergy  |
| H2001     | 50 50            | 1.3 6.9             | 0.10      | Synergy  |
| H1893     | 50 50            | 1.7 6.8             | 0.10      | Synergy  |

2.3. Time–Kill Assay

Figures 1–6 express the results of the time–kill assay of the six strains, when exposed to AMX and 1,8-cineole, alone or in combination, in MHB over 24 h. The application of 1,8-cineole or AMX alone (at their MICs) or in combination in all tested bacteria caused a significant reduction in bacterial counts ($p < 0.05$) in comparison with the control assay. No significant difference was found among the counts of all bacteria with AMX or 1,8-cineole alone ($p > 0.05$). However, 2-log reduction was obtained after 24 h of exposure when they were combined compared with either drug alone. Exposure of tested bacteria to the combination of AMX at IC50 and 1,8-cineole at IC40 resulted in a significant drop in the bacterial counts, and a 2-log reduction after only 4 h of exposure and a 4-log reduction after 8 h of exposure were obtained for all tested bacteria compared with the control. These results showed a significant inhibitory effect of AMX/1,8-cineole combinations on the cell viability of the tested bacteria.
Figure 1. Time–kill curve of control assay, AMX alone at MIC (open squares), 1,8-cineole alone at MIC (filled circles) and AMX/1,8-cineole in combination at MIC (open triangles) against the *E. coli* P956 strain. The values that include different letters are significantly different from each other at \( p < 0.05 \).

Figure 2. Time–kill curve of control assay, AMX alone at MIC (open squares), 1,8-cineole alone at MIC (filled circles) and AMX/1,8-cineole in combination at MIC (open triangles) against the *E. coli* P933 strain. The values that include different letters are significantly different from each other at \( p < 0.05 \).
Figure 3. Time–kill curve of control assay, AMX alone at MIC (open squares), 1,8-cineole alone at MIC (filled circles) and AMX/1,8-cineole in combination at MIC (open triangles) against the *E. coli* P7847 strain. The values that include different letters are significantly different from each other at $p < 0.05$.

Figure 4. Time–kill curve of control assay, AMX alone at MIC (open squares), 1,8-cineole alone at MIC (filled circles) and AMX/1,8-cineole in combination at MIC (open triangles) against the *K. pneumoniae* H1878 strain. The values that include different letters are significantly different from each other at $p < 0.05$. 

Figure 5. Time–kill curve of control assay, AMX alone at MIC (open squares), 1,8-cineole alone at MIC (filled circles) and AMX/1,8-cineole in combination at MIC (open triangles) against the K. pneumoniae H2001 strain. The values that include different letters are significantly different from each other at $p < 0.05$.

Figure 6. Time–kill curve of control assay, AMX alone at MIC (open squares), 1,8-cineole alone at MIC (filled circles) and AMX/1,8-cineole in combination at MIC (open triangles) against the K. pneumoniae H1893 strain. The values that include different letters are significantly different from each other at $p < 0.05$.

2.4. Enzymatic Assay

The results of the calculated percentage inhibition of positive controls and experimental tube toward E. coli-sensitive strain are given in Table 6. Total growth inhibition was observed when AMX was applied alone at MIC. No growth inhibition was observed when 1,8-cineole was applied alone at sub-MIC and when the $\beta$-lactamase was added to AMX at MIC. When adding both $\beta$-lactamase and 1,8-cineole (at sub-MIC) to AMX (at MIC), the calculated percentage inhibition was $83.4\% \pm 1.1$. 
Table 6. Percent growth inhibition of *E. coli* strain in positive controls and experimental tube. The values that include different letters are significantly different from each other at *p* < 0.05.

| Positive controls          | % Inhibition        |
|----------------------------|---------------------|
| AMX                        | 100% ± 0.0 a        |
| 1,8-cineole                | 0% ± 0.0 c          |
| AMX + β-lactamase          | 0% ± 0.0 c          |
| β-lactamase + 1,8-cineole + AMX | 83.4% ± 1.1 b |

3. Discussion

The main aim of this study was, first, to evaluate the antibacterial activity of a β-lactam antibiotic AMX associated with an EO major compound (1,8-cineole) towards clinical isolates of *E. coli* and *K. pneumoniae* ESBL-producing strains. All tested bacteria were resistant to the AMX. The MIC values obtained were 50 mg/L for AMX and 100 mg/L for 1,8-cineole. Associations between AMX and 1,8-cineole were made at partial inhibitory concentrations (IC 50% and IC 25% for AMX and IC 40%, IC 30% and IC 20% for 1,8-cineole). Total growth inhibition of all tested bacterial strains was obtained when AMX (at IC 50%) was associated with 1,8-cineole (at IC 40%). The MIC of associated AMX was around 25 times less than that of the single substance; the MIC of associated 1,8-cineole was about 15 times smaller than that of the single substance. FICI values were five times less than 0.5 for the association AMX/1,8-cineole. This synergy has been demonstrated in the time–kill experiments. Our results agree with previous literature data, which reported a high synergistic effect between Amoxicillin/clavulanic acid and 1,8-cineole on *Staphylococcus aureus* resistant to methicillin [13]. Currently, several studies reported synergistic interactions of essential oils such as *Thymus zygis* or *Thymus atlanticus* with antimicrobial agents including ampicillin, ciprofloxacin and vancomycin against *S. aureus*, *K. pneumoniae* and *E. coli* [14–16].

To our knowledge, the mechanism responsible for the synergetic action resulting from the combination of antibiotics and EO major compounds remains to be defined [17,18]. Nevertheless, recent studies have elucidated the mechanism of action of antibiotics associated with some essential oils against resistant bacteria [15,19].

Dumlupinar et al. [20] showed detailed cell damage of *K. pneumoniae* after treatment with a combination of *Pelargonium endlicherianum* essential oil with gentamicin and cefepime, by using scanning electron microscopy (SEM), resulting in increased efficacy of these antibiotics. In another study [19], the same authors proved that there was a synergistic effect of ampicillin associated with *Pelargonium endlicherianum* essential oil on *Neisseria meningitidis*. The results of this study illustrated that essential oils have two effects, the first, to increase membrane-permeability activity, and the second, to show that it had phagocytic activity in human leukocyte cells.

The most commonly known mechanism of resistance to β-lactam antibiotics is the production of β-lactamase [7,21], which is based on the hydrolysis of the β-lactam ring inactivating the drug. β-lactamase inhibitors such as clavulanic acid and sulbactam have been used to face antimicrobial resistance [22,23]. However, resistance to these β-lactamase inhibitors has also been reported [24,25].

Although producing ESBL, the six tested strains were very sensitive to the AMX/1,8-cineole associations. This observation led us to the hypothesis that the presence of 1,8-cineole might influence the β-lactamase enzymatic reaction. To verify this hypothesis, we have realized an enzymatic assay based on the simulation of the following β-lactamase enzymatic reactions in presence of 1,8-cineole:

Active β-lactamase + AMX = Bacterial Growth

Inactive β-lactamase + AMX = Growth Inhibition

As a bacterial growth indicator, the *E. coli* strain selected to be used in this assay was sensitive to β-lactam antibiotics and did not produce any β-lactamase enzyme. 1,8-cineole
was used at sub-inhibitory concentrations to only observe the antibacterial activity of AMX. Therefore, no antibacterial activity of 1,8-cineole was observed.

Compared with AMX tested alone, in the presence of the β-lactamase, no growth inhibition was obtained. These results show that β-lactamase completely prevents the antibacterial activity of AMX. In contrast, when AMX is combined with 1,8-cineole, its antibacterial activity is protected in the presence of β-lactamase. The results obtained were comparable to those obtained in the absence of the β-lactamase enzyme. Knowing that 1,8-cineole was used at sub-MIC, the obtained antibacterial activity is due solely to AMX. This can be explained by the fact that the combination of AMX with 1,8-cineole clearly influences the enzymatic reaction by decreasing the affinity of AMX to β-lactamase.

In conclusion, through the use of partial inhibitory concentrations (PIC), we have demonstrated a strong synergistic action when AMX is associated with 1,8-cineole tested at very minimal concentrations on the six clinical isolates of ESBL-producing bacterial strains. The results show that the antibacterial activity of AMX on ESBL-producing strains can be rehabilitated by associating AMX with 1,8-cineole. We obtained similar results when 1,8-cineole was replaced by carvacrol or eugenol EO major compounds (data not shown). Likewise, results demonstrate the synergistic effects when gentamicin or tetracycline are combined with α-pinene, thymol, eugenol or carvacrol against S.aureus, E.coli and Aeruginosa strains [26].

Secondly, we have demonstrated with the enzymatic assay that the association of AMX and 1,8-cineole protects the antibiotic by considerably decreasing β-lactam affinity to β-lactamase.

These results are supported by a spectroscopic study that demonstrates that the addition of 1,8-cineole allows the rearrangement of amoxicillin molecules in solution in the form of oligomers of 3–4 amoxicillin molecules [27]. Similar results were obtained with AMX/Clavulanic acid and ampicillin when associated with 1,8-cineole, Carvacrol or Eugenol EO major compounds (data not shown).

These findings support previous studies published in our patent in which we have demonstrated that combining AMX with EO major compounds reduces the probability of selection of resistant mutants [28].

This new concept was tested in vivo on animals and humans (clinical trials), and the results obtained (data not shown) open the path to a new drug currently commercialized by Sothema under the name Olipen (AMM: DMP/21/NPPdDMP/VHA/18). This product is used in therapy to overcome bacterial resistance to β-lactam antibiotics while reducing the rate of resistance prevalence.

4. Materials and Methods

4.1. Culture Media

Mueller–Hinton agar (MHA) and Mueller–Hinton broth (MHB) (BIOKAR, Allonne France) were prepared and sterilized according to the manufacturers’ instructions.

4.2. Bacterial Strains

In this study, six ESBL-producing strains were used: three E. coli strains (P956, P933 and P7847) and three K. pneumoniae strains (H1878, H2001 and H1893). They were clinically isolated and obtained from the laboratory of bacteriology of the University Hospital Center (Centre Hospitalier Universitaire Hassan II—CHU) in Fez, Morocco. E. coli ATCC 8739 strain, sensitive to β-lactam antibiotics, was used as a test of microorganism for the enzymatic assay. It was provided by the National Institute of Hygiene (INH, Rabat, Morocco).

The inoculum suspension was obtained by taking colonies from 24 h cultures on tryptic soy agar. These colonies were suspended in sterile saline (0.9% NaCl) and shaken for 15 s. The density was adjusted using previously established optical density/concentration standard curves. The suspensions were then diluted in MHB to reach the final concentrations ($2 \times 10^7$ CFU/mL for the six clinical isolates and $3.3 \times 10^6$ CFU/mL for E. coli ATCC 8739).
4.3. Antibacterial Agents

Amoxicillin was purchased from Sigma Aldrich, Saint-Quentin-Fallavier, France (CAS Number: 26787-78-0) and diluted in sterile distilled water to obtain stock solutions (400 mg/L). EO major compound, 1,8-cineole, obtained from Sigma Aldrich (CAS Number: 470-82-6) was diluted in 0.2% (v/v) agar according to the method described by Remmal et al. [29].

4.4. β-Lactamase Enzyme

The β-lactamase enzyme was obtained from Sigma Aldrich (CAS Number: 9073-60-3). It was prepared according to the manufacturer’s instructions.

4.5. Determination of Partial Inhibitory Concentrations (PIC) of AMX and 1,8-Cineole Using a Microplate Assay Technique

The PIC of AMX and 1,8-cineole against the six bacterial strains were measured by the microplate assay [29,30] in MHB using sterile separate microplates (96 wells, 200 µL working well volume). Twelve serial dilutions of AMX (50–0.025 mg/L) and 1,8-cineole (100–0.05 mg/L) were prepared in sterile hemolysis tubes by successive dilutions 1/2. A measure of 100 µL of each dilution were introduced horizontally into twelve wells. Bacterial suspensions were then diluted in MH broth and plated in 96-well plates at a density of $2 \times 10^7$ CFU/mL. Negative control was prepared by adding 200 µL of MHB to the twelve horizontal wells. Positive controls were prepared by adding 150 µL of MHB and 50 µL from bacterial suspension ($2 \times 10^7$ CFU/mL) to the twelve horizontal wells. Each concentration was performed in triplicate. The optical density was determined by a spectrophotometer (Versamax, Molecular Devices) at 540 nm at 0 h, and 22 h after incubation at 37 °C. The inhibition percentage of the six strains in the presence of each of the two antibacterial agents was calculated using the following formula [30]:

$$\% \text{ inhibition} = \left[ 1 - \frac{(\text{ODT22} - \text{ODT0})}{(\text{ODC22} - \text{ODC0})} \right] \times 100$$

ODT0: OD of experimental well at 0 h.
ODT22: OD of experimental well after 22 h incubation.
ODC0: OD of positive control well at 0 h.
ODC22: OD of positive control well after 22 h incubation.

4.6. Checkerboard Assay

The determined PIC of AMX (IC50 and IC25) and 1,8-cineole (IC40, IC30 and IC20) were used to make different associations. The following associations of AMX and 1,8-cineole were prepared in sterile tubes:

- AMX at IC50 + 1,8-cineole at IC40
- AMX at IC50 + 1,8-cineole at IC30
- AMX at IC50 + 1,8-cineole at IC20
- AMX at IC25 + 1,8-cineole at IC40
- AMX at IC25 + 1,8-cineole at IC30
- AMX at IC25 + 1,8-cineole at IC20

The antibacterial activity that resulted from these associations was evaluated using the microplate assay technique described previously. In a separate microplate for each strain, every association was prepared in triplicate by adding 50 µL of the prepared solution, 50 µL from suspension of microorganisms ($2 \times 10^7$ CFU/mL) and 100 µL of MHB. For each antibacterial agent, every PIC was prepared in triplicate. A negative control was prepared in triplicate by adding 200 µL of MHB to the twelve horizontal wells. A positive control
was prepared in triplicate by adding 150 µL of MHB and 50 µL from the suspension of microorganisms (2 × 10⁷ CFU/mL) to the twelve horizontal wells. As described previously, the OD at 0 h and after 22 h of incubation at 37 °C was determined to calculate the inhibition percentage.

For each microorganism, the AMX/1,8-cineole associations were deemed synergistic, indifferent or antagonistic by calculating the fractional inhibitory concentration index (FICI) using the formula for each agent [13]:

\[ \Sigma \text{FICI} = \text{FIC} (A) + \text{FIC} (B). \]

FIC (A) = (MIC (A) in combination/MIC (A) alone); FIC (B) = (MIC (B) in combination/MIC (B) alone). The index values of the fractional inhibitory concentrations are interpreted as follows: FIC ≤ 0.5 = synergy; 0.5 < FIC ≤ 0.75 = partial synergy; 0.76 ≤ FIC ≤ 1.0 = additive; 1 < FIC ≤ 4 = no interaction (not differential); and FIC > 4 = antagonism.

4.7. Time–Kill Assay

The time–kill experiments were performed with selected antibacterial associations according to the results of the checkerboard assay. AMX and 1,8-cineole were tested alone and in association at MIC [31,32]. The mixtures were inoculated with an overnight culture of each of the six tested strains adjusted to a final density of 2 × 10⁷ CFU/mL. After 0, 2, 4, 6, 8 and 24 h of incubation at 37 °C, aliquots were withdrawn and diluted with physiological saline solution. The dilutions were spread onto MHA and the colonies were counted after incubation at 37 °C for 24 h. The number of colonies was expressed as log CFU/mL. Reduction in viable cell count ≥2 log₁₀ after 24 h incubation in comparison with the cell count of the most active single substance was interpreted as synergy [31].

4.8. Enzyme Assay

The ß-lactamase assay was investigated to clarify whether 1,8-cineole had inhibitory activity on this enzyme. In preliminary studies, we determined the MIC of AMX and the sub-inhibitory concentration (Sub-MIC) of 1,8-cineole toward E. coli-sensitive strain using the microplate assay technique as already described above [29,30]. They were, respectively, 6 mg/L and 0.002 mg/L (data not shown). A suspension of 3.3 × 10⁶ CFU/mL was prepared from an overnight preculture of the tested strain grown in MHB at 37 °C. Positive controls and experimental tubes were prepared in triplicate according to Table 7. Using a spectrophotometer, the optical densities (OD) of each tube were determined at 540 nm at 0 h, and 22 h after incubation at 37 °C. The inhibition percentage of E. coli tested strain in each tube was then calculated as described previously [30].

Table 7. Inocula, AMX, 1,8-cineole and ß-lactamase tubes content.

| Positive controls | MHB | Inocula ¹ | AMX ² | ß-lactamase ³ | 1,8-cineole ⁴ |
|------------------|-----|-----------|-------|--------------|--------------|
| PC1 1000 µL      |     | –         | –     | –            | –            |
| PC2 970 µL       | 30  µL | –        | –     | –            | –            |
| PC3 940 µL       | 30  µL | 30 µL    | –     | –            | –            |
| PC4 940 µL       | 30  µL | –        | –     | –            | 30 µL        |
| PC5 930 µL       | 30  µL | 30 µL    | 30 µL | 10 µL        | –            |
| Assay 900 µL     | 30  µL | 30 µL    | 30 µL | 10 µL        | 30 µL        |

¹ 3.3 × 10⁶ CFU/mL of E. coli tested strain. ² AMX was used at MIC (6 mg/L). ³ ß-lactamase was used at 0.03 U/mL. ⁴ 1,8-cineole was used at sub-MICs (0.002 mg/L).

4.9. Data Analysis

For each tested strain, all experiments were performed in triplicate. These data were analyzed with Student’s t-test and one-way ANOVA followed by Tukey’s multiple
comparison test (Graph Pad Prism, version 5.03). Differences of $p < 0.05$ were considered statistically significant.

5. Conclusions

Our results show that the AMX/1,8-cineole association could be exploited in therapy to overcome bacterial resistance to AMX while reducing the rate of resistance prevalence.

6. Patents

Pharmaceutical Formulation Comprising Cineole and Amoxicillin (2019). https://patentscope.wipo.int/search/en/detail.jsf?docId=US250863563&docAn=16306262 (accessed on 1 June 2022).

Author Contributions: Conceptualization, A.R., N.C. and A.A.A.; methodology, A.R. and A.A.A.; software, S.H., H.C., M.T. and A.M.; validation, A.R. and N.C.; formal analysis, A.R. and A.A.A.; investigation; A.R. and A.A.A.; resources, S.H., H.C., M.T., A.M. and A.A.A.; data curation, A.A.A.; writing—original draft preparation, A.A.A. and S.H.; writing—review and editing, S.H., H.C., M.T. and A.M.; visualization, H.C., M.T. and A.M.; supervision, A.R. and N.C. All authors have read and agreed to the published version of the manuscript.

Funding: All authors confirm that this study did not receive any funding during this research. However, the article processing charge (APC) was funded by Sothema laboratory (Address: BP 20180-Z.I Bouskoura-Morocco).

Data Availability Statement: The data used to support the findings of this study are available from the corresponding author upon request.

Acknowledgments: This work is a partial fulfillment of Ahmed Amin Akhmouch’s PhD thesis; it was supported by a grant from the University Sidi Mohamed Ben Abdallah for the Laboratory of Biotechnology. The authors thank Helene Mock and Soukayna Remmal for their assistance in checking the English of the manuscript.

Conflicts of Interest: The authors declare that there are no conflict of interest related to this research paper.

References

1. Bhusal, R.P.; Barr, J.J.; Subedi, D.A. Metabolic perspective into antimicrobial tolerance and resistance. *Lancet Microbe* 2022, 3, e160–e161. [CrossRef]

2. Taati, M.M.; Amirmozafari, N.; Shariati, A.; Hallajzadeh, M.; Mirkalantari, S.; Khoshbayan, A.; Masjedian, J.F. How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections. *Infect. Drug Resist.* 2020, 13, 45–61. [CrossRef]

3. WHO. Antimicrobial Resistance: Global Report on Surveillance. 2014. Available online: https://apps.who.int/iris/bitstream/handle/10665/112647/WHO_HSE_PED_AIP_2014_1.pdf?sequence=1 (accessed on 1 April 2022).

4. Gautret, P.; Lagier, J.C.; Parola, P.; Meddeb, L.; Sevestre, J.; Mailhe, M.; Doudier, B.; Aubry, C.; Amrane, S.; Seng, P.; et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. *Travel Med. Infect. Dis.* 2020, 34, 101663. [CrossRef]

5. Lanckohr, C. Rational use of antibiotics in the era of multi-resistance. *Anästh. Intensivmed.* 2022, 63, 24–32. [CrossRef]

6. Mansour, T.S.; Bradford, P.A.; Venkatesan, A.M. Recent Developments in β-Lactamases and Inhibitors. *Annu. Rep. Med. Chem.* 2008, 43, 247–267. [CrossRef]

7. Tansawai, U.; Walsh, T.R.; Niumsup, P.R. Extended spectrum β-lactamase-producing *Escherichia coli* among backyard poultry farms, farmers, and environments in Thailand. *Poult. Sci.* 2019, 98, 2622–2631. [CrossRef] [PubMed]

8. Dembele, R.; Kaboré, W.A.; Soulama, I.; Traoré, O.; Ouédraogo, N.; Konaté, A.; Guissend, N.K.; N’Golo, D.C.; Sanou, A.; Serme, S.; et al. Molecular Characterization of β-Lactamase Producing Genes and Integrons in Diarrheagenic *Escherichia Coli* from Diarrheal Children Less than Five Years of Age in Ouagadougou, Burkina Faso. *Res. Square* 2021, accepted. Available online: https://www.researchsquare.com (accessed on 1 June 2022).

9. Chaves, T.P.; Pinheiro, R.E.E.; Melo, E.S.; Soares, M.J.D.S.; Souza, J.S.N.; de Andrade, T.B.; de Lemos, T.L.G.; Coutinho, H.D. Essential oil of Eucalyptus camaldulensis Dehn potentiates β-lactam activity against *Staphylococcus aureus* and *Escherichia coli* resistant strains. *Ind. Crop. Prod.* 2018, 112, 70–74. [CrossRef]

10. Das, T.; Nandy, S.; Mukherjee, A.; Nongdiam, P.; Dey, A. Plant Essential Oils for Combating Antimicrobial Resistance via Re-potentiating the Fading Antibiotic Arsenal. *Antimicrob. Resist.* 2022, 419–485. [CrossRef]

11. Langeveld, W.T.; Veldhuizen, E.J.A.; Burt, S.A. Synergy between essential oil components and antibiotics: A review. *Crit. Rev. Microbiol.* 2014, 40, 76–94. [CrossRef]
12. Yap, P.S.X.; Lim, S.H.E.; Hu, C.P.; Yiap, B.C. Combination of essential oils and antibiotics reduce antibiotic resistance in plasmid-conferred multidrug resistant bacteria. *Phytochem* 2013, 70, 710–713. [CrossRef]

13. Hriouech, S.; Akhmouch, A.A.; Mzabi, A.; Cheffhoua, H.; Tanghort, M.; Oumokhtar, B.; Chami, N.; Remmal, A. The Antistaphylococcal Activity of Amoxicillin/Clavulanic Acid, Gentamicin, and 1,8-Cineole Alone or in Combination and Their Efficacy through a Rabbit Model of Methicillin-Resistant *Staphylococcus aureus* Osteomyelitis. *Evid.-Based Compl. Altern. Med.* 2020, 2020, 4271017. [CrossRef] [PubMed]

14. Coimbra, A.; Miguel, S.; Ribeiro, M.; Coutinho, P.; Silva, L.; Duarte, A.P.; Ferreira, S. *Thymus zygis* Essential Oil: Phytochemical Characterization, Bioactivity Evaluation and Synergistic Effect with Antibiotics against *Staphylococcus aureus*. *J. Antibiot.* 2022, 11, 146. [CrossRef]

15. Ju, J.; Xie, Y.; Yu, H.; Guo, Y.; Cheng, Y.; Qian, H.; Yao, W. Synergistic interactions of plant essential oils with antimicrobial agents: A new antimicrobial therapy. *Crit. Rev. Food Sci. Nutr.* 2022, 62, 1740–1751. [CrossRef] [PubMed]

16. Nafis, A.; Iriti, M.; Ouchari, L.; El Otmani, F.; Marraiki, N.; Elgorban, A.M.; Syed, A.; Mezrioui, N.; Hassani, L.; Custódio, L. New Insight into the Chemical Composition, Antimicrobial and Synergistic Effects of the Moroccan Endemic *Thymus atlanticus* (Ball) Roussine Essential Oil in Combination with Conventional Antibiotics. *Molecules* 2021, 26, 5850. [CrossRef] [PubMed]

17. Aelenei, P.; Miron, A.; Trifan, A.; Bujor, A.; Gille, E.; Aprotosoaie, A.C. Essential Oils and Their Components as Modulators of Antibiotic Activity against Gram-Negative Bacteria. *Medicines* 2016, 3, 19. [CrossRef]

18. Karumathil, D.P.; Nair, M.S.; Gaffney, J.; Kollanoor-Johny, A.; Venkitanarayanan, K. Trans-Cinnamaldehyde and Eugenol Increase *Acinetobacter baumannii* Sensitivity to Beta-Lactam Antibiotics. *Front. Microbiol.* 2018, 9, 1011. [CrossRef] [PubMed]

19. Dumlupinar, B.; Celik, D.D.; Gürer, Ü.S.; Demirci, B.; Gürbüz, B.; Kurtulus, E.M. Synergic potential of *Neisseria meningitidis* and *Haemophilus influenzae*. *S. Afr. J. Bot.* 2022, 146, 243–253. [CrossRef]

20. Dumlupinar, B.; Celik, D.D.; Gürer, Ü.S.; Demirci, B.; Gurbuz, B.; Kurtulus, E.M. Synergic potential of *Neisseria meningitidis* and *Haemophilus influenzae*. *S. Afr. J. Bot.* 2020, 135, 117–126. [CrossRef]

21. Tang, S.S.; Apisarnthanarak, A.; Hsu, L.Y. Mechanisms of β-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria. *Adv. Drug Delivery Rev.* 2014, 78, 3–13. [CrossRef]

22. Bush, K.; Bradford, P.A. β-Lactams and β-Lactamase Inhibitors: An Overview. Cold. Spring. *Harb. Perspect. Med.* 2016, 6, a025247. [CrossRef]

23. Fernandes, R.; Amador, P.; Prudêncio, C. β-Lactams: Chemical structure, mode of action and mechanisms of resistance. *Rev. Med. Microbiol.* 2013, 24, 7–17. [CrossRef]

24. Oteo, J.; Campos, J.; Lázaro, E.; Cuevas, Ó.; García-Cobos, S.; Pérez-Vázquez, M.; De Abajo, F.J.; Spanish Members of EARSS, S.M. Increased Amoxicillin–Clavulanic Acid Resistance in *Escherichia coli* Blood Isolates, Spain. *Emerg. Infect. Dis.* 2008, 14, 1259–1262. [CrossRef] [PubMed]

25. Rodríguez-Villodres, A.; Gil-Marqués, M.L.; Alvarez-Marn, R.; Bonnin, R.A.; Pachón-Ibáñez, M.E.; Aguilar-Guisado, M.; Naas, T.; Aznar, J.; Pachón, J.; Lepe, J.A.; et al. Extended-spectrum resistance to β-lactams/β-lactamase inhibitors (ESRI) evolved from low-level resistant *Escherichia coli*: *J. Antimicrob. Chemother.* 2020, 75, 77–85. [CrossRef] [PubMed]

26. Özçel, Y.; Yılmaz, U.; Unlü, M.; Unlü, G.V. Antibacterial Activity and Synergistic Interaction of Various Essential Oil Components and Antibiotics. *Microbiyoloji Bulletin*. 2022, 56, 95–102. [CrossRef] [PubMed]

27. Remmal, A.; Akhmouch, A.A. Pharmaceutical Formulation Comprising Cineole and Amoxicillin. 2019. Patent. Available online: https://patentscope.wipo.int/search/en/detail.jsf?docId=US250863563&docAn=16306262 (accessed on 1 June 2022).

28. Remmal, A. Pharmaceutical Composition Comprising an Anti-Bacterial Agent and an Active Ingredient Selected from Carveol, Thymol, Eugenol, Borneol and Carvacrol. 2006. Patent. Available online: https://patents.google.com/patent/WO2006120567A2/en (accessed on 1 June 2022).

29. Remmal, A.; Bouchikhi, T.; Rhayour, K.; Ettayebi, M.; Tantaoui-Elaraki, A. Improved Method for the Determination of Antimicrobial Activity of Essential Oils in Agar Medium. *J. Essent. Oil Res.* 1993, 5, 179–184. [CrossRef]

30. Casey, J.T.; O’Cleirigh, C.; Walsh, P.K.; O’Shea, D.G. Development of a robust microtiter plate-based assay method for assessment of bioactivity. *J. Microbiol. Methods* 2004, 58, 327–334. [CrossRef]

31. Matsumura, S.O.; Louie, L.; Louie, M.; Simor, A.E. Synergy Testing of Vancomycin-Resistant *Enterococcus faecium* against Quinupristin-Dalfopristin in Combination with Other Antimicrobial Agents. *Antimicrob Agents Chemother.* 1999, 43, 2776–2779. [CrossRef]

32. Mulyaningsih, S.; Sporer, F.; Zimmermann, S.; Reichling, J.; Wink, M. Synergistic properties of the terpenoids aromadendrene and 1,8-cineole from the essential oil of Eucalyptus globulus against antibiotic-susceptible and antibiotic-resistant pathogens. *Phytochem* 2010, 17, 1061–1066. [CrossRef]